Navigation Links
Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
Date:12/11/2008

LAS VEGAS, Dec. 11 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the company's Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccines induced T-cell responses against a matching strain of influenza virus and demonstrated cross-clade antibody responses against a different strain in a Phase 1 clinical trial. The company previously reported that the vaccines had achieved potentially protective levels of antibody responses in up to 67% of evaluable subjects in the trial's higher dose cohorts. Vical researchers presented the expanded data, as well as new nonclinical data from the company's RapidResponse(TM) DNA vaccine manufacturing program, this week at the DNA Vaccines 2008 Conference (Las Vegas - December 9-11).

H5N1 Pandemic Influenza Vaccine Phase 1 Trial Update

New data presented at the conference indicates that the company's monovalent Vaxfectin(R)-formulated H5N1 pandemic influenza DNA vaccine induced T-cell responses against the H5 antigen in 75% to 100% of evaluable subjects in the various cohorts. T-cell responses could be important in protecting against serious disease and in limiting the spread of disease during an outbreak.

The monovalent vaccine, which was based on the H5N1 influenza virus strain, A/Vietnam/1203/04, also induced antibody responses against the H5N1 influenza virus strain, A/Hong Kong/156/97 from a different clade, in 50% of responders. Cross-clade responses could be important in providing protection against emerging strains of influenza before a matching vaccine could be deployed.

Antibody and/or T-cell responses against the matching H5 antigen
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
2. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
5. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
6. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
7. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
9. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
10. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
11. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...wswire/--ZargisMedicalCorp.,asubsidiaryofSpeedusCo...Research(NYSE: SI ),todayannouncedthatitsZargisCar...eofCBS, TheEarlyShow duringasegmentinwhichMarkJann...ewinningproductsfromthepublication,s2009"BestofWha...dtelevisionmorningnewstalkshowbroadcastbyCBSfromNe...
(Date:11/24/2009)...wire/-- InfiniteMind ,aSaltLakeCitybasedsoftwareco...rogrameyeQ,thesoftwareprogramistobeusedinconjuncti... wasintroducedattheCOVDconferencethisOctoberinColo...lbelievesthe eyeQ programaddssignificantvaluetohis...lowshispatientstoembedpracticesfromtheofficesettin...
(Date:11/24/2009).../PRNewswire-FirstCall/--CardioGenicsHoldingsInc.(O...ductstargetingtheimmunoassaysegmentoftheIVDtesting...isprogressingtothenextphaseofthecommercializationo...eads("Beads"). ,, PertheagreementwithMerckChimi...edMerckChimiewithitsproprietarysilvercoatedparamag...
Breaking Medicine Technology:Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Infinite Mind Announces the Launch of a New Online Vision Therapy Program eyeQ 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 3Taskwise receives Editors Pick Award from BrotherSoft 61495 1Taskwise receives Editors Pick Award from BrotherSoft 61495 2Taskwise receives Editors Pick Award from BrotherSoft 61495 3Give a Gift that Gives Back With Yoga Sandals 28R 29 Comfys 61494 1Give a Gift that Gives Back With Yoga Sandals 28R 29 Comfys 61494 2Sabalcore Computing Has Selected Scalable Informatics as Their Primary Storage Vendor 14863 1Sabalcore Computing Has Selected Scalable Informatics as Their Primary Storage Vendor 14863 2
...ONCONASE for,Treatment of Neuroblastoma, BLOOMFIEL...lfacell Corporation today announced that new data ...is active against naive and,chemoresistant neurobl...ivo data published in Cancer,Letters (2007; Vol. 2...een Alfacell and Martin Michaelis, M.D., Ph.D., at...
...07 - PrimeCell(TM),Therapeutics LLC (http://www.pr...rovided research support and pre-clinical,studies ...lity and,efficacy of implanting autologous bone ma...ents., Dr. Luis Geffner presented a preliminary re...al Society for Cellular Therapy,held here June 24...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for,Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical,Study 2
(Date:11/25/2009)...ease may make a case for population-wide reduction...ealthDay News) -- It,s known that eating a lot of ...ssure. Now there,s confirmation of a corollary: Hi...eater risk of cardiovascular disease and stroke. ...ion of BMJ found that a difference of just 5 gra...
(Date:11/25/2009)... is evolving beyond the treatment of cavities and ...king at these more traditional practices in a whol...teeth is what the public expects form dentistry, w...mportant part of the medical team. The increasingl...is being strengthened every day by new and ongoing...
(Date:11/25/2009)...how to optimize your Emergency Department,s manage... cases this season? Should you test all patients ...Which - if any - antiviral should you prescribe? E...ergency Medicine Practice, which presents the very...nfluenza diagnosis and treatment. , ...
(Date:11/25/2009)...ckages.com, California,s designated Premier Partne...ness during the November 15 - December 31 Annual E...nroll in a zero-cost PPO Medicare Advantage plan. ...available through BenefitPackages.com to eligible ...abasas, CA (PRWEB) November 25, 2009 -- The state ...
(Date:11/24/2009)...ally provide accurate preliminary interpretation o...en attending neuroradiologist unavailable, accordi...l I trauma center published in the December issue ...gy ( JACR ). , The accuracy of image interpret...radiology. In most training programs, radiology re...
Breaking Medicine News(10 mins):Health News:Local Dentist Teaches Other Dentists How to Save the Lives of Their Patients 2Health News:Local Dentist Teaches Other Dentists How to Save the Lives of Their Patients 3Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 2Health News:Emergency Medicine Practice Publishes 'Influenza: Challenges in Diagnosis and Management in the Emergency Department' 3Health News:BenefitPackages.com Reveals the Truth About No or Low Cost Medicare Supplement Plan Options Including Anthem Blue Cross Freedom Blue Regional PPO 2
... of Rochester Medical Center study challenges comm...), by showing that in some people, surprisingly hi...r as long as 24 hours. The finding suggests that B...hed the research online January 28, 2009. , Cont...
..., Calif., Jan. 27 Nationwide Health Properties, I...y will release its fourth quarter earnings on Wedn...g on the New York Stock Exchange. The Company wil...l performance and operating results for the fourth...
...LLEY, Minn., Jan. 27 Minnesotans with chronic,con... their health and,independence under the proposed ...are policy experts at Minneapolis-based Courage Ce... tragic,accident," said Jan Malcolm, CEO of Courag...
... Minn., Jan. 27 As Governor Pawlenty released his...aders to find a balanced approach to protecting vu...t cuts. , , "Older Minnesotans have been among... said State Director Michele Kimball. "This crisi...
...icials say company distributed ,adulterated, peanu...SDAY, Jan. 27 (HealthDay News) -- The Georgia faci...ste involved in the salmonella outbreak had in the...ns the now-closed Blakely, Ga., plant, shipped pea...
...ep Forward for Patient-Provider Decision Making , ...ts America , , WASHINGTON, Jan. 27 "The Senate ...arch (CER) package from the House by focusing the ...th, the nation,s leading Hispanic health advocacy ...
Other Medicine News:Health News:Rochester study raises new questions about controversial plastics chemical 2Health News:Rochester study raises new questions about controversial plastics chemical 3Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 2Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 3Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 2Health News:Courage Center Experts Disagree With Gov. Pawlenty's Proposed Budget Cuts 3Health News:AARP to State Leaders: Protect Vulnerable Minnesotans from Severe Budget Cuts 2Health News:AARP to State Leaders: Protect Vulnerable Minnesotans from Severe Budget Cuts 3Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill 2
...EBV laboratory diagnosis is generally confirmed by...rity of the disease however, is not indicated by t...IM occurs in 10 - 20 percent of children. Detecti...essary to fully ascertain the stage of EBV infecti...
...IDI-Strep B test can lower healthcare costs with b...ays. By identifying mothers colonized with group B...ed and effective antibiotic prophylaxis. This can ... reduce unnecessary antibiotic use in uncolonized ...
...y Bard® Biopsy Instrument and Needle is specia...l: a large quality, reliable core sample. All need...aturing ultra-sharp tips and polished surfaces for...y systems and needle sizes assures an ideal match ...
... to obtain multiple core biopsies of soft tissue. ...y Needle design facilitates one-handed control. Pr... tissue sample. Beveled point stylet permits easy ...surrounding tissue. Sharp cutting edge of cannula ...
Medicine Products: